Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Catch ’em all! CDK9’s RUNX1 mega evolution

Ashley P. Ng

Blood (2024) 144 (17): 1758–1759.

https://doi.org/10.1182/blood.2024026377

Published: 2024

Journal Articles

Hit the road JAK, don’t P-STAT, stem more!

Ashley P. Ng

Blood (2024) 144 (7): 683–684.

https://doi.org/10.1182/blood.2024025441

Published: 2024

Journal Articles

A Rare Cell State Underpins Diverse Mechanisms of Adaptive Resistance to CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

James A Kuzich, Laure Talarmain, Dane Vassiliadis, Andrew A Guirguis, Jack D Chan, Paul A Beavis, Phillip K Darcy, Ashley P Ng, Mark A Dawson

Blood (2023) 142 (Supplement 1): 887.

https://doi.org/10.1182/blood-2023-191111

Published: 2023

Journal Articles

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Blood (2023) 142 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2023-178473

Published: 2023

Journal Articles

All wired up: heptads in hematopoiesis

Ashley P. Ng

Blood (2023) 142 (17): 1407–1409.

https://doi.org/10.1182/blood.2023022014

Published: 2023

Journal Articles

Iron homeostasis governs erythroid phenotype in polycythemia vera

Blood (2023) 141 (26): 3199–3214.

https://doi.org/10.1182/blood.2022016779

Published: 2023

Includes: Supplemental data

Journal Articles

Blinatumomab in Combination with an Intensive Pediatric Protocol Results in High Rates of Day 79 MRD Negativity in Adolescent and Young Adult Acute Lymphoblastic Leukemia - Preliminary Results of the Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 "Sublime” Study

Blood (2022) 140 (Supplement 1): 8971–8972.

https://doi.org/10.1182/blood-2022-168568

Published: 2022

Journal Articles

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Al-Ola Abdallah, Andrew J Cowan, Xavier Leleu, Cyrille Touzeau, Brea Lipe, Eva Medvedova, Caitlin Costello, Jens Hillengass, P. Leif Bergsagel, Raya Mawad, Henning Schade, Daniel Morillo Giles, Albert Oriol, Yifah Yaron, Patrick P Ng, Sumit Madan

Blood (2022) 140 (Supplement 1): 7284–7285.

https://doi.org/10.1182/blood-2022-159665

Published: 2022

Journal Articles

Diagnostic Utility of Multimodal Genomic Profiling for Molecular Classification and MRD Assessment in Adult B-Cell Acute Lymphoblastic Leukemia

Georgina L Ryland, Ashish Bajel, Michael Dickinson, Paul G Ekert, Oliver Hofmann, Maarten IJzerman, Ashley P Ng, Alicia Oshlack, Breon Schmidt, Ing S Tiong, Martin Vu, David Alan Westerman, Sean Grimmond, Piers Blombery

Blood (2021) 138 (Supplement 1): 274.

https://doi.org/10.1182/blood-2021-146396

Published: 2021

Journal Articles

The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma

Patrick P Ng, Wade Aaron, Evan Callihan, Golzar Hemmati, Che-Leung Law, Abdel Kareem Azab, Laura Sun

Blood (2021) 138 (Supplement 1): 1185.

https://doi.org/10.1182/blood-2021-151880

Published: 2021

Journal Articles

Unraveling a T-ALL Tapestri

Ashley P. Ng

Blood (2021) 137 (6): 726–727.

https://doi.org/10.1182/blood.2020008467

Published: 2021

Journal Articles

The ITK Inhibitor Cpi-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and Is Active in a Murine Model of ALPS

V. Koneti Koneti Rao, MD FRCPA, Patrick P. Ng, PhD, Craig M. Hill, PhD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-137631

Published: 2020

Journal Articles

Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis

Hai Vu Nguyen, Cassandra J. Vandenberg, Ashley P. Ng, Mikara R. Robati, Natasha S. Anstee, Joel Rimes, Edwin D. Hawkins, Suzanne Cory

Blood (2020) 135 (13): 1019–1031.

https://doi.org/10.1182/blood.2019003014

Published: 2020

Includes: Supplemental data

Journal Articles

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng, PhD, Mehrdad Mobasher, MD MPH, Kitman S. Yeung, MS, Andrew N. Hotson, PhD, Craig M. Hill, PhD, Antonett Madriaga, MS, Trang P. Dao-Pick, MA, Erik Verner, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD

Blood (2019) 134 (Supplement_1): 1571.

https://doi.org/10.1182/blood-2019-127338

Published: 2019

Journal Articles

I myelofibrosis! Veni VitD! Et tu, macrophage?

Ashley P. Ng

Blood (2019) 133 (15): 1613–1615.

https://doi.org/10.1182/blood-2019-02-900779

Published: 2019

Journal Articles

Identification of Potent BH3-Mimetic Combinations Targeting Pro-Survival Pathways in Human B-Cell Acute Lymphoblastic Leukemia

Donia M Moujalled, PhD, Diane T Hanna, Giovanna Pomilio, Veronique Litalien, Shaun Fleming, Marie Chanrion, Ana-Leticia Maragno, Laurence Kraus-Berthier, Seong Lin Khaw, Guillaume Lessene, David Huang, Andrew W. Roberts, MBBS, PhD, Olivier Geneste, Paul G Ekert, Ashley P Ng, Andrew H Wei, MBBS,PhD

Blood (2018) 132 (Supplement 1): 567.

https://doi.org/10.1182/blood-2018-99-114051

Published: 2018

Journal Articles

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

Patrick P. Ng, Daniel K. Lu, Juthamas Sukbuntherng, Jutta K. Neuenburg, Danelle F. James, Betty Y. Chang, PhD

Blood (2015) 126 (23): 3998.

https://doi.org/10.1182/blood.V126.23.3998.3998

Published: 2015

Journal Articles

Unsupervised Discovery of Early Markers of Erythroid Maturation in Human Donor Marrow

David P Ng, MD, Brent Wood, MD PhD

Blood (2014) 124 (21): 4304.

https://doi.org/10.1182/blood.V124.21.4304.4304

Published: 2014

Journal Articles

B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)–infected patients rarely react with the viral proteins

Patrick P. Ng, Chiung-Chi Kuo, Stanley Wang, Shirit Einav, Luca Arcaini, Marco Paulli, Carol S. Portlock, Joseph Marcotrigiano, Alexander Tarr, Jonathan Ball, Ronald Levy, Shoshana Levy

Blood (2014) 123 (10): 1512–1515.

https://doi.org/10.1182/blood-2013-10-532895

Published: 2014

Journal Articles

Screening With Spirometry Is A Useful Predictor Of Later Development Of Non-Infectious Pulmonary Syndromes In Patients Undergoing Allogeneic Stem Cell Transplantation

Thompson A Philip, MBBS, FRACP, FRCPA, Andrew B M Lim, MBBS, FRACP, FRCPA, Mark Tacey, Ramzi Hijazi, MBBS, Ashley P. Ng, MBBS, BMedSc, PhD, FRACP, FRCPA, Jeffrey Szer, BMedSc, MBBS, FRACP, David Ritchie, MBBS, PhD, FRACP, FRCPA, Ashish R. Bajel, MBBS, FRACP, FRCPA

Blood (2013) 122 (21): 4603.

https://doi.org/10.1182/blood.V122.21.4603.4603

Published: 2013

NARROW

Catch ’em all! CDK9’s RUNX1 mega evolution

Hit the road JAK, don’t P-STAT, stem more!

A Rare Cell State Underpins Diverse Mechanisms of Adaptive Resistance to CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

All wired up: heptads in hematopoiesis

Iron homeostasis governs erythroid phenotype in polycythemia vera

Blinatumomab in Combination with an Intensive Pediatric Protocol Results in High Rates of Day 79 MRD Negativity in Adolescent and Young Adult Acute Lymphoblastic Leukemia - Preliminary Results of the Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 "Sublime” Study

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Diagnostic Utility of Multimodal Genomic Profiling for Molecular Classification and MRD Assessment in Adult B-Cell Acute Lymphoblastic Leukemia

The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma

Unraveling a T-ALL Tapestri

The ITK Inhibitor Cpi-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and Is Active in a Murine Model of ALPS

Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

I myelofibrosis! Veni VitD! Et tu, macrophage?

Identification of Potent BH3-Mimetic Combinations Targeting Pro-Survival Pathways in Human B-Cell Acute Lymphoblastic Leukemia

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

Unsupervised Discovery of Early Markers of Erythroid Maturation in Human Donor Marrow

B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)–infected patients rarely react with the viral proteins

Screening With Spirometry Is A Useful Predictor Of Later Development Of Non-Infectious Pulmonary Syndromes In Patients Undergoing Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only